Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status
Open Access
Abstract
Poly (ADP-ribose) polymerase (PARP) inhibition in BRCA-mutated cells results in an incapacity to repair DNA damage, leading to cell death caused by synthetic lethality. Within the treatment options for advanced triple negative breast cancer, the PARP inhibitor olaparib is only given to patients with BRCA1/2 mutations. However, these patients may show resistance to this drug and BRCA1/2 wild-type tumors can show a striking sensitivity, making BRCA status a poor biomarker for treatment choice. Aiming to investigate if the zebrafish model can discriminate sensitivities to olaparib, we developed zebrafish xenografts with different BRCA status and measured tumor response to treatment, as well as its impact on angiogenesis and metastasis. When challenged with olaparib, xenografts revealed sensitivity phenotypes independent of BRCA. Moreover, its combination with ionizing radiation increased the cytotoxic effects, showing potential as a combinatorial regimen. In conclusion, we show that the zebrafish xenograft model may be used as a sensitivity profiling platform for olaparib in monotherapy or in combinatorial regimens. Hence, this model presents as a promising option for the future establishment of patient-derived xenografts for personalized medicine approaches beyond BRCA status.Keywords
Funding Information
- Fundação Champalimaud (168)
- Fundação para a Ciência e a Tecnologia (FCT-PTDC/MEC-ONC/31627/2017, Congento (LISBOA-01-0145-FEDER-022170)
This publication has 104 references indexed in Scilit:
- Increased PARP-1 Association with DNA in Alkylation Damaged, PARP-Inhibited Mouse FibroblastsMolecular Cancer Research, 2012
- Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor XenograftMolecular Cancer Therapeutics, 2011
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Evaluation of the Value of Attribution in the Interpretation of Adverse Event Data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group InvestigationJournal of Clinical Oncology, 2010
- 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancersNature Structural & Molecular Biology, 2010
- Synthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEMBO Molecular Medicine, 2009
- The emerging role of nuclear architecture in DNA repair and genome maintenanceNature Reviews Molecular Cell Biology, 2009
- Transparent Adult Zebrafish as a Tool for In Vivo Transplantation AnalysisCell Stem Cell, 2008
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004